Targeted Therapies in Adult B-Cell Malignancies

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Oct 2

PMID 26425544

Citations 8

Authors

Jean-Francois Rossi

Affiliations

Soon will be listed here.

Abstract

B-lymphocytes are programmed for the production of immunoglobulin (Ig) after antigen presentation, in the context of T-lymphocyte control within lymphoid organs. During this differentiation/activation process, B-lymphocytes exhibit different restricted or common surface markers, activation of cellular pathways that regulate cell cycle, metabolism, proteasome activity, and protein synthesis. All molecules involved in these different cellular mechanisms are potent therapeutic targets. Nowadays, due to the progress of the biology, more and more targeted drugs are identified, a situation that is correlated with an extended field of the targeted therapy. The full knowledge of the cellular machinery and cell-cell communication allows making the best choice to treat patients, in the context of personalized medicine. Also, focus should not be restricted to the immediate effects observed as clinical endpoints, that is, response rate, survival markers with conventional statistical methods, but it should consider the prediction of different clinical consequences due to other collateral drug targets, based on new methodologies. This means that new reflection and new bioclinical follow-up have to be monitored, particularly with the new drugs used with success in B-cell malignancies. This review discussed the principal aspects of such evident bioclinical progress.

Citing Articles

The Pt(-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.

Silconi Z, Rosic V, Benazic S, Radosavljevic G, Mijajlovic M, Pantic J Int J Mol Sci. 2022; 23(15).

PMID: 35897737 PMC: 9332548. DOI: 10.3390/ijms23158161.

MYC inhibitors in multiple myeloma.

Martinez-Martin S, Soucek L Cancer Drug Resist. 2022; 4(4):842-865.

PMID: 35582389 PMC: 8992455. DOI: 10.20517/cdr.2021.55.

BAFF, involved in B cell activation through the NF-κB pathway, is related to disease activity and bone destruction in rheumatoid arthritis.

Zhang L, Xiao H, Zhang F, Wu Y, Shu J, Li Y Acta Pharmacol Sin. 2021; 42(10):1665-1675.

PMID: 33483588 PMC: 8463593. DOI: 10.1038/s41401-020-00582-4.

Paeoniflorin-6'-O-benzene sulfonate alleviates collagen-induced arthritis in mice by downregulating BAFF-TRAF2-NF-κB signaling: comparison with biological agents.

Shu J, Zhang X, Han L, Zhang F, Wu Y, Tang X Acta Pharmacol Sin. 2018; 40(6):801-813.

PMID: 30446734 PMC: 6786314. DOI: 10.1038/s41401-018-0169-5.

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.

Siveen K, Prabhu K, Achkar I, Kuttikrishnan S, Shyam S, Khan A Mol Cancer. 2018; 17(1):31.

PMID: 29455667 PMC: 5817858. DOI: 10.1186/s12943-018-0788-y.

References

Auger-Quittet S, Duny Y, Daures J, Quittet P . Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis. Cancer Med. 2014; 3(4):927-38. PMC: 4303160. DOI: 10.1002/cam4.247. View

Gea-Banacloche J . Rituximab-associated infections. Semin Hematol. 2010; 47(2):187-98. DOI: 10.1053/j.seminhematol.2010.01.002. View

Jourdan M, Cren M, Robert N, Bollore K, Fest T, Duperray C . IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia. 2014; 28(8):1647-56. DOI: 10.1038/leu.2014.61. View

Warburg O . On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-70. View

Salot S, Bercegeay S, Dreno B, Saiagh S, Scaglione V, Bonnafous C . Large scale expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS "TCR gamma/delta+ T cell isolation kit". J Immunol Methods. 2009; 347(1-2):12-8. DOI: 10.1016/j.jim.2009.05.006. View

Kelloff G, Hoffman J, Johnson B, Scher H, Siegel B, Cheng E . Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005; 11(8):2785-808. DOI: 10.1158/1078-0432.CCR-04-2626. View

Challagundla P, Medeiros L, Kanagal-Shamanna R, Miranda R, Jorgensen J . Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014; 142(6):837-44. DOI: 10.1309/AJCPBV9ELXC0ECVL. View

Mackay F, Schneider P, Rennert P, Browning J . BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2002; 21:231-64. DOI: 10.1146/annurev.immunol.21.120601.141152. View

Aalipour A, Advani R . Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol. 2014; 5(4):121-33. PMC: 4212313. DOI: 10.1177/2040620714539906. View

10.

Han T, Fan L, Li J, Xu W . Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy. Cancer Biol Ther. 2013; 15(1):3-9. PMC: 3938521. DOI: 10.4161/cbt.26607. View

11.

Press O, Leonard J, Coiffier B, Levy R, Timmerman J . Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program. 2001; :221-40. DOI: 10.1182/asheducation-2001.1.221. View

12.

Calandra G, Bridger G, Fricker S . CXCR4 in clinical hematology. Curr Top Microbiol Immunol. 2010; 341:173-91. DOI: 10.1007/82_2010_26. View

13.

Wiestner A . Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2012; 31(1):128-30. DOI: 10.1200/JCO.2012.44.4281. View

14.

Wijdenes J, Vooijs W, Clement C, Post J, Morard F, Vita N . A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996; 94(2):318-23. DOI: 10.1046/j.1365-2141.1996.d01-1811.x. View

15.

Hwang J, Kuruvilla J, Mendelson D, Pishvaian M, Deeken J, Siu L . Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res. 2010; 16(15):4038-45. PMC: 3703245. DOI: 10.1158/1078-0432.CCR-10-0822. View

16.

Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi J . T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?. Hum Pathol. 2007; 39(2):194-200. DOI: 10.1016/j.humpath.2007.05.026. View

17.

Bezbradica J, Medzhitov R . Role of ITAM signaling module in signal integration. Curr Opin Immunol. 2012; 24(1):58-66. DOI: 10.1016/j.coi.2011.12.010. View

18.

Mukhopadhyay A, Ni J, Zhai Y, Yu G, Aggarwal B . Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem. 1999; 274(23):15978-81. DOI: 10.1074/jbc.274.23.15978. View

19.

Martin-Antonio B, Najjar A, Robinson S, Chew C, Li S, Yvon E . Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ. 2014; 22(1):96-107. PMC: 4262774. DOI: 10.1038/cdd.2014.120. View

20.

Dal Porto J, Gauld S, Merrell K, Mills D, Pugh-Bernard A, Cambier J . B cell antigen receptor signaling 101. Mol Immunol. 2004; 41(6-7):599-613. DOI: 10.1016/j.molimm.2004.04.008. View